West Pharma Q2 FY26 EPS rises 18.1% to $2.15; net sales increase 13.8% to $872.3 million

West Pharmaceutical Services posted Q2 2026 net sales of $872.3 million, up 13.8% from a year earlier; GAAP diluted EPS rose 18.1% to $2.15.

GAAP net income climbed to $154 million; GAAP operating profit increased to $179.1 million.

Full-year net sales guidance was raised to $3.345 billion-$3.38 billion; adjusted-diluted EPS guidance increased to $8.85-$9.05.

Proprietary Products net sales rose 16.6% to $722.6 million, led by HVP Components up 19.4% to $424.1 million.

Operating cash flow was $213.9 million; capital expenditures were $85.9 million.